Glenmark Pharma Targets 12–15% Revenue Growth with Margin Expansion Path Ahead

💊

has set ambitious financial targets, projecting 12–15% revenue growth and EBITDA margins of 23%, with a roadmap to expand margins above 25% in the long term. The company also aims to deliver strong return ratios of 25–30% ROCE and 20–25% ROE. Its subsidiary IGI plans an annual investment of $70–75 million to support strategic growth initiatives and reinforce long-term value creation.